Nadim S. Jafri, MD, MSc; Carlton A. Hornung, PhD, MPH; Colin W. Howden, MD
Potential Financial Conflicts of Interest:Consultancies: C.W. Howden (Meretek, TAP, Takeda, Santarus, Novartis); Honoraria: C.W. Howden (AstraZeneca, Meretek, Santarus); Grants received: C.W. Howden (AstraZeneca).
Requests for Single Reprints: Colin W. Howden, MD, Division of Gastroenterology, Northwestern University Feinberg School of Medicine, 676 North St. Clair Street, Suite 1400, Chicago, IL 60611; e-mail, mailto:email@example.com.
Current Author Addresses: Dr. Jafri: University of Louisville, 550 South Jackson Street, ACB 3rd Floor, Louisville, KY 40202.
Dr. Hornung: University of Louisville School of Public Heath and Information Sciences, 4063 K Building, 555 South Floyd Street, Louisville, KY 40202.
Dr. Howden: Division of Gastroenterology, Northwestern University Feinberg School of Medicine, 676 North St. Clair Street, Suite 1400, Chicago, IL 60611.
Jafri N., Hornung C., Howden C.; Meta-analysis: Sequential Therapy Appears Superior to Standard Therapy for Helicobacter pylori Infection in Patients Naive to Treatment. Ann Intern Med. 2008;148:923-931. doi: 10.7326/0003-4819-148-12-200806170-00226
Download citation file:
Published: Ann Intern Med. 2008;148(12):923-931.
Standard proton-pump inhibitor–based therapy for Helicobacter pylori infection fails in up to one quarter of patients. Sequential therapy may be more efficacious.
To compare sequential therapy with standard triple therapy for H. pylori infection.
MEDLINE, EMBASE (1981 to October 2007), the Cochrane Central Register of Controlled Trials, and Google Scholar. PubMed and Ovid were the search engines used.
Randomized, controlled trials (RCTs) comparing sequential and standard triple therapies in treatment-naive patients with documented H. pylori infection.
3 reviewers independently assessed trial eligibility and quality and extracted data on eradication.
The crude rates of H. pylori eradication in 10 RCTs involving 2747 patients were 93.4% (95% CI, 91.3% to 95.5%) for sequential therapy (n = 1363) and 76.9% (CI, 71.0% to 82.8%) for standard triple therapy (n = 1384) (relative risk reduction, 71% [CI, 64% to 77%]; absolute risk reduction, 16 percentage points [CI, 14 to 19 percentage points]). The median rates of adherence were 97.4% (range, 90.0% to 98.9%) for sequential therapy and 96.8% (range, 93.0% to 100%) for standard therapy. Sequential therapy appeared superior in prespecified sensitivity (subgroup) analyses stratified by trial quality; smoking status; diagnosis (ulcer disease or nonulcer dyspepsia); resistance to clarithromycin, imidazoles, or both; duration of triple therapy; and method of diagnosis. Both treatments had similar side effect profiles.
Only 1 study was double-blinded. Most patients were from Italy. There was clear evidence of publication bias.
Sequential therapy appears superior to standard triple therapy for eradication of H. pylori infection. If RCTs in other countries confirm these findings, 10-day sequential therapy could become a standard treatment for H. pylori infection in treatment-naive patients.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Gastroenterology/Hepatology, Infectious Disease, Peptic Disease, H. Pylori.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only